Lilly's Weight Pill: More Side Effects, Better Results?

Eli Lilly recently disclosed detailed data from a head-to-head trial comparing its experimental weight-loss drug, orforglipron, with Novo Nordisk's oral semaglutide, used for type 2 diabetes. The findings highlight a nuanced comparison of their side effect profiles and efficacy.

In the study, 58% of patients on a 36-milligram dose of orforglipron reported mild-to-moderate side effects like nausea and diarrhea. This compares to 45% of patients taking a 14-milligram dose of oral semaglutide. Consequently, about 10% of orforglipron users discontinued the treatment due to these effects, double the 5% rate seen with semaglutide.

Despite the increased side effects, orforglipron demonstrated significant benefits. Patients on the 36 mg dose of orforglipron achieved an average weight loss of 9.2% (8.9 kg or 19.7 lb), substantially more than the 5.3% (5 kg or 11 lb) weight loss observed with the 14 mg dose of semaglutide. Furthermore, orforglipron led to better blood glucose control, lowering average levels by 2.2% compared to 1.4% with semaglutide.

Eli Lilly emphasized that the enhanced glycemic control and weight loss offered by orforglipron present a favorable trade-off for patients. The drug, like semaglutide, mimics the GLP-1 hormone, known for its appetite-suppressing qualities.